HOME >> MEDICINE >> NEWS
Hormone therapy may still offer important health benefits to postmenopausal women

(SACRAMENTO, Calif.) -- Despite the highly publicized closing of the Women's Health Initiative study, the scientific community should not rule out that women may benefit from hormone therapy after menopause, say researchers at UC Davis, Duke and Harvard Universities. Their review of the scientific literature on the biology of estrogens and progestins appears in the May 28 issue of the journal Science.

"It was right to close the Women's Health Initiative trial," said Judith L. Turgeon, professor of internal medicine at UC Davis School of Medicine and senior author of the Science article. "But we should not generalize the results of this trial and overlook the real potential that other forms of hormone therapy may offer to postmenopausal women."

The Women's Health Initiative trials used the steroid formulation most frequently prescribed in the United States at the time, given to women in pill form on a daily basis. New information gleaned from basic research in the biology of ovarian hormones, however, indicates that not all estrogens and progestins are alike, nor do they behave identically in different tissues in the body.

"As our understanding of the biology of these hormones grows, the more we realize how important certain factors are -- such as formulation, dosage, whether they're given by a pill or a patch, and characteristics of women being treated," said co-author Phyllis M. Wise, dean of the division of biological sciences and distinguished professor of neurobiology, physiology and behavior at UC Davis. "More targeted therapies may yield important health benefits."

Estrogens affect many tissues in the body. During natural menopause, which occurs in women at an average age of 51 years, estrogen and progesterone secretion from the ovaries diminish. Afterwards, the risk of coronary heart disease and osteoporosis increases. Stroke and dementia are also associated with aging.

"Estrogens and progestins provi
'"/>

Contact: Carole Gan
916-734-9047
University of California, Davis - Health System
27-May-2004


Page: 1 2 3

Related medicine news :

1. Hormone therapy increases risk of urinary incontinence
2. Hormone therapy controversy raises drug safety issues
3. Endocrine Society and Hormone Foundation call for increased research
4. Hormone may offer hope for treating some behavioral disorders
5. Hormone found to protect bones
6. Hormone released by bone marrow cells may hasten recovery from brain injury
7. Hormones increase side effects, complicate treatment decision for prostate cancer patients
8. Hormones and drugs that control blood pressure also control malaria infection
9. Hormone replacement therapy reviewing the evidence
10. Hormone prompts adult stem cells to differentiate into islet cells
11. Hormone therapy study stopped due to increased breast cancer risk, lack of overall benefit

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/28/2017)... ... 28, 2017 , ... Guide to FDA and EU Medical Device Regulations: 2017 ... side of the Atlantic devicemakers do business, this fully updated and expanded guide keeps ... addition to the full text of the FDA’s regulations in 21 CFR Parts 800 ...
(Date:6/28/2017)... (PRWEB) , ... June 28, 2017 , ... David B. Sosin, a founding ... Illinois, took over the post of 2nd Vice President for the Illinois State Bar ... installed as the ISBA’s 3rd Vice President in 2016 following a state-wide election and served ...
(Date:6/28/2017)... Columbia (PRWEB) , ... June 28, 2017 , ... ... (FSE: ZEON) is pleased to announce that a two year study conducted by ... Company's Bromley Creek zeolite was successful in remediating potash brine-impacted groundwater. As a ...
(Date:6/28/2017)... (PRWEB) , ... June 28, 2017 , ... ... consulting firm servicing communities throughout the greater Cincinnati metropolitan area, is teaming up ... temporary lodgings for families with children receiving treatment in nearby hospitals. , Ronald ...
(Date:6/27/2017)... ... 2017 , ... Harbour , a DAO (decentralized autonomous organization) that harnesses ... released their technical specifications . , 2017 has seen an explosion of token ... determining which offerings will garner the greatest ROI. Dean Eigenmann, Co-founder and CEO of ...
Breaking Medicine News(10 mins):
(Date:6/9/2017)... Calif. , June 9, 2017 AirXpanders, ... company focused on the design, manufacture, sale and distribution ... market on the progress of its commercial roll-out in ... now available in more than one hundred (100) medical ... AeroForm offers a needle-free alternative for women ...
(Date:6/7/2017)... Endo International plc (NASDAQ: ENDP ... Joseph R. Goodwin , U.S. District Court Judge ... , entered a case management order in MDL ... Liability Litigation (the "MDL") that includes a provision requiring ... disclosures on specific causation within one hundred twenty (120) ...
(Date:6/3/2017)... , June 3, 2017  Eli Lilly ... announced that results from the Phase 3 MONARCH ... (CDK)4 & 6 inhibitor, in combination with fulvestrant, ... with fulvestrant alone in women with hormone-receptor-positive (HR+), ... breast cancer who have relapsed or progressed after ...
Breaking Medicine Technology:
Cached News: